Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience.

Indian J Ophthalmol · 2024 · PMC467021 · PMID 38648453

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

did not reach statistical significanceP = 0.059so close (0.05 < p ≤ 0.1)

At month 12, the mean BCVA was statistically significantly better in the ranibizumab group than in the dexamethasone group ( P = 0.008), whereas the difference in mean BCVA did not reach statistical significance between the aflibercept–dexamethasone groups despite the mean BCVA showing a better value in the former one ( P = 0.059).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.